Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Rev Esp Enferm Dig ; 114(1): 58-59, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34517711

RESUMO

The aim of the IBDU is to provide comprehensive care for patients with IBD (1,2). During the COVID-19 pandemic, telephone medical consultations and telemedicine training sessions were implemented to ensure patient safety (3). The aim of this study was to determine whether there was a difference in the degree of satisfaction between face-to-face and telephone care, as well as in the annual patient sessions.


Assuntos
COVID-19 , Doenças Inflamatórias Intestinais , Hospitais , Humanos , Doenças Inflamatórias Intestinais/epidemiologia , Doenças Inflamatórias Intestinais/terapia , Pandemias , Satisfação do Paciente , Satisfação Pessoal , SARS-CoV-2 , Telefone
2.
Rev. esp. enferm. dig ; 113(1): 60-64, ene. 2021. tab
Artigo em Espanhol | IBECS | ID: ibc-199891

RESUMO

La población de pacientes con enfermedad inflamatoria intestinal (EII) y trasplante de órgano sólido (TOS) va en aumento. Existen dos escenarios clínicos: la recurrencia de la EII preexistente al TOS, que es más frecuente, y la aparición de EII de novo, cuya incidencia es mucho más elevada que la de la población general. El curso clínico de ambas es diferente y puede tener impacto negativo en el injerto. Los mecanismos fisiopatológicos se desconocen. No existen recomendaciones específicas de tratamiento. La combinación entre la terapia biológica de la EII y el régimen inmunosupresor, para evitar el rechazo, obliga a una vigilancia estrecha para detectar infecciones, eventos autoinmunes y neoplasias. El cáncer colorrectal (CCR) está aumentando en esta población. El grupo de mayor riesgo es el de trasplante hepático (TH) por colangitis esclerosante (CEP) con EII


No disponible


Assuntos
Humanos , Doenças Inflamatórias Intestinais/etiologia , Doenças Inflamatórias Intestinais/epidemiologia , Transplante de Órgãos/efeitos adversos , Diarreia/diagnóstico , Complicações Pós-Operatórias , Doenças Inflamatórias Intestinais/diagnóstico , Imunossupressores/uso terapêutico , Diagnóstico Diferencial , Diarreia/terapia , Colectomia , Colite Ulcerativa/complicações
3.
Rev Esp Enferm Dig ; 113(1): 60-64, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33233912

RESUMO

The population of patients with inflammatory bowel disease (IBD) and solid organ transplant (SOT) is increasing. Two clinical scenarios exist, recurrence of pre-existing IBD, which is more common, and de novo development of IBD, with a much higher incidence than in the general population. Their clinical course differs and may have a negative impact on the graft in both cases. The pathophysiological mechanisms remain unknown and no specific treatment recommendations are available. The combined effect of biologic therapy against IBD and immunosuppressive therapy against a potential rejection means that close monitoring is mandatory to identify infection, autoimmune events and malignancies. The colorectal cancer (CRC) rate is higher in this population. The group at greatest risk are patients with IBD undergoing liver transplantation (LT) for primary sclerosing cholangitis (PSC).


Assuntos
Colangite Esclerosante , Colite , Doenças Inflamatórias Intestinais , Transplante de Fígado , Colangite Esclerosante/epidemiologia , Colangite Esclerosante/cirurgia , Humanos , Doenças Inflamatórias Intestinais/epidemiologia , Doenças Inflamatórias Intestinais/terapia , Fatores de Risco
4.
World J Gastroenterol ; 21(40): 11282-303, 2015 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-26525013

RESUMO

In recent years, the incidence of inflammatory bowel disease (IBD) has been on the rise, extending to countries where it was infrequent in the past. As a result, the gap between high and low incidence countries is decreasing. The disease, therefore, has an important economic impact on the healthcare system. Advances in recent years in pharmacogenetics and clinical pharmacology have allowed for the development of treatment strategies adjusted to the patient profile. Concurrently, new drugs aimed at inflammatory targets have been developed that may expand future treatment options. This review examines advances in the optimization of existing drug treatments and the development of novel treatment options for IBD.


Assuntos
Anti-Inflamatórios/uso terapêutico , Descoberta de Drogas/tendências , Fármacos Gastrointestinais/uso terapêutico , Doenças Inflamatórias Intestinais/tratamento farmacológico , Terapia de Alvo Molecular/tendências , Animais , Anti-Inflamatórios/farmacocinética , Previsões , Fármacos Gastrointestinais/farmacocinética , Humanos , Incidência , Doenças Inflamatórias Intestinais/diagnóstico , Doenças Inflamatórias Intestinais/epidemiologia , Farmacogenética/tendências
5.
World J Gastroenterol ; 20(5): 1211-27, 2014 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-24574796

RESUMO

Inflammatory bowel disease (IBD) affects a part of the young population and has a strong impact upon quality of life. The underlying etiology is not known, and the existing treatments are not curative. Furthermore, a significant percentage of patients are refractory to therapy. In recent years there have been great advances in our knowledge of stem cells and their therapeutic applications. In this context, autologous hematopoietic stem cell transplantation (HSCT) has been used in application to severe refractory Crohn's disease (CD), with encouraging results. Allogenic HSCT would correct the genetic defects of the immune system, but is currently not accepted for the treatment of IBD because of its considerable risks. Mesenchymal stem cells (MSCs) have immune regulatory and regenerative properties, and low immunogenicity (both autologous and allogenic MSCs). Based on these properties, MSCs have been used via the systemic route in IBD with promising results, though it is still too soon to draw firm conclusions. Their local administration in perianal CD is the field where most progress has been made in recent years, with encouraging results. The next few years will be decisive for defining the role of such therapy in the management of IBD.


Assuntos
Colite Ulcerativa/terapia , Doença de Crohn/terapia , Transplante de Células-Tronco Hematopoéticas , Intestinos , Transplante de Células-Tronco Mesenquimais , Animais , Colite Ulcerativa/diagnóstico , Colite Ulcerativa/imunologia , Colite Ulcerativa/fisiopatologia , Doença de Crohn/diagnóstico , Doença de Crohn/imunologia , Doença de Crohn/fisiopatologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Intestinos/imunologia , Intestinos/patologia , Intestinos/fisiopatologia , Transplante de Células-Tronco Mesenquimais/efeitos adversos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...